Six Insiders Into a One-Year-Old Cardio Bet
Braveheart Bio didn't exist before 2024, and now six insiders have piled in over the past 30 days. Travis Murdoch, the CEO, just put $1.5 million down at $18 a share, and that's the highest-conviction role in the book. This is a clinical-stage biotech chasing a heart muscle drug, so the whole thing rides on trial data you can't see yet. The cluster is real and the CEO check carries weight, but you're betting on a science story with no price history to lean on. Size it like the binary it is.
The Filing
| Ticker | BRVE |
| Company | Braveheart Bio, Inc. |
| Insider | Travis Murdoch, CEO and President |
| Buy amount | $1.5M |
| Filing date | August 7, 2026 |
| Conviction | Interesting · 53/100 |
| Setup type | Insufficient Data |
Ultimate members received this analysis in real time.